TY  - JOUR
AU  - Bikbov, Boris
AU  - Soler, Maria Jose ́
AU  - Pešić, Vesna
AU  - Capasso, Giovambattista
AU  - Unwin, Robert
AU  - Endres, Matthias
AU  - Remuzzi, Giuseppe
AU  - Perico, Norberto
AU  - Gansevoort, Ron
AU  - Mattace-Raso, Francesco
AU  - Bruchfeld, Annette
AU  - Figurek, Andreja
AU  - Hafez, Gaye
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4031
AB  - Kidney dysfunction can profoundly influence many organ systems, and recent evidence suggests a potential role for increased albuminuria in the development of mild cognitive impairment (MCI) or dementia. Epidemiological studies conducted in different populations have demonstrated that the presence of increased albuminuria is associated with a higher relative risk of MCI or dementia both in cross-sectional analyses and in studies with long-term follow-up. The underlying pathophysiological mechanisms of albuminuria's effect are as yet insufficiently studied, with several important knowledge gaps still present in a complex relationship with other MCI and dementia risk factors. Both the kidney and the brain have microvascular similarities that make them sensitive to endothelial dysfunction involving different mechanisms, including oxidative stress and inflammation. The exact substrate of MCI and dementia is still under investigation, however available experimental data indicate that elevated albuminuria and low glomerular filtration rate are associated with significant neuroanatomical declines in hippocampal function and grey matter volume. Thus, albuminuria may be critical in the development of cognitive impairment and its progression to dementia. In this review, we summarize the available evidence on albuminuria's link to MCI and dementia, point to existing gaps in our knowledge and suggest actions to overcome them. The major question of whether interventions that target increased albuminuria could prevent cognitive decline remains unanswered. Our recommendations for future research are aimed at helping to plan clinical trials and to solve the complex conundrum outlined in this review, with the ultimate goal of improving the lives of patients with chronic kidney disease.
PB  - Oxford University Press
T2  - Nephrology Dialysis Transplantation
T1  - Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?
VL  - 37
IS  - supplement 2
SP  - ii55
EP  - ii62
DO  - 10.1093/ndt/gfab261
ER  - 

@article{
author = "Bikbov, Boris and Soler, Maria Jose ́ and Pešić, Vesna and Capasso, Giovambattista and Unwin, Robert and Endres, Matthias and Remuzzi, Giuseppe and Perico, Norberto and Gansevoort, Ron and Mattace-Raso, Francesco and Bruchfeld, Annette and Figurek, Andreja and Hafez, Gaye",
year = "2022",
abstract = "Kidney dysfunction can profoundly influence many organ systems, and recent evidence suggests a potential role for increased albuminuria in the development of mild cognitive impairment (MCI) or dementia. Epidemiological studies conducted in different populations have demonstrated that the presence of increased albuminuria is associated with a higher relative risk of MCI or dementia both in cross-sectional analyses and in studies with long-term follow-up. The underlying pathophysiological mechanisms of albuminuria's effect are as yet insufficiently studied, with several important knowledge gaps still present in a complex relationship with other MCI and dementia risk factors. Both the kidney and the brain have microvascular similarities that make them sensitive to endothelial dysfunction involving different mechanisms, including oxidative stress and inflammation. The exact substrate of MCI and dementia is still under investigation, however available experimental data indicate that elevated albuminuria and low glomerular filtration rate are associated with significant neuroanatomical declines in hippocampal function and grey matter volume. Thus, albuminuria may be critical in the development of cognitive impairment and its progression to dementia. In this review, we summarize the available evidence on albuminuria's link to MCI and dementia, point to existing gaps in our knowledge and suggest actions to overcome them. The major question of whether interventions that target increased albuminuria could prevent cognitive decline remains unanswered. Our recommendations for future research are aimed at helping to plan clinical trials and to solve the complex conundrum outlined in this review, with the ultimate goal of improving the lives of patients with chronic kidney disease.",
publisher = "Oxford University Press",
journal = "Nephrology Dialysis Transplantation",
title = "Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?",
volume = "37",
number = "supplement 2",
pages = "ii55-ii62",
doi = "10.1093/ndt/gfab261"
}

Bikbov, B., Soler, M. J. ́., Pešić, V., Capasso, G., Unwin, R., Endres, M., Remuzzi, G., Perico, N., Gansevoort, R., Mattace-Raso, F., Bruchfeld, A., Figurek, A.,& Hafez, G.. (2022). Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?. in Nephrology Dialysis Transplantation
Oxford University Press., 37(supplement 2), ii55-ii62.
https://doi.org/10.1093/ndt/gfab261

Bikbov B, Soler MJ́, Pešić V, Capasso G, Unwin R, Endres M, Remuzzi G, Perico N, Gansevoort R, Mattace-Raso F, Bruchfeld A, Figurek A, Hafez G. Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?. in Nephrology Dialysis Transplantation. 2022;37(supplement 2):ii55-ii62.
doi:10.1093/ndt/gfab261 .

Bikbov, Boris, Soler, Maria Jose ́, Pešić, Vesna, Capasso, Giovambattista, Unwin, Robert, Endres, Matthias, Remuzzi, Giuseppe, Perico, Norberto, Gansevoort, Ron, Mattace-Raso, Francesco, Bruchfeld, Annette, Figurek, Andreja, Hafez, Gaye, "Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?" in Nephrology Dialysis Transplantation, 37, no. supplement 2 (2022):ii55-ii62,
https://doi.org/10.1093/ndt/gfab261 . .